Development of a clinically relevant prototype cell transfer sheet (CTS) to act as an artificial Bruchs membrane in the treatment of Age related Macular Degeneration (AMD)
Lead Participant:
BIOMER TECHNOLOGY LIMITED
Abstract
AMD is the leading cause of blindness in the Western world affecting an estimated 30 million people worldwide.
Biomer Technology Limited is developing a cell based therapy approach for Age related Macular Degeneration (AMD) to anatomically re-engineer the Bruch’s membrane-Retinal Pigment Epithelial (RPE) cell complex, the first of its kind to target the structure that may be responsible for the disease.
The novel cell transfer sheet (CTS) which will allow the seeding and transplantation of RPE cells into the sub retinal space is based upon a proprietary polymeric biomaterial film that has been laser processed to provide a controlled uniform porosity to allow nutrient transport across the CTS to the cells.
Biomer Technology Limited is developing a cell based therapy approach for Age related Macular Degeneration (AMD) to anatomically re-engineer the Bruch’s membrane-Retinal Pigment Epithelial (RPE) cell complex, the first of its kind to target the structure that may be responsible for the disease.
The novel cell transfer sheet (CTS) which will allow the seeding and transplantation of RPE cells into the sub retinal space is based upon a proprietary polymeric biomaterial film that has been laser processed to provide a controlled uniform porosity to allow nutrient transport across the CTS to the cells.
Lead Participant | Project Cost | Grant Offer |
|---|---|---|
| BIOMER TECHNOLOGY LIMITED | £31,725 | £ 23,794 |
People |
ORCID iD |
| Simon Dixon (Project Manager) |